B. Riley Securities analyst Madison El-Saadi initiates coverage on Neuronetics (NASDAQ:STIM) with

Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regul

Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's

Neuronetics (NASDAQ:STIM) narrows FY2026 sales outlook from $160.000 million-$166.000 million to $16

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.05) per share which beat the analyst cons

Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroSta

BTIG initiates coverage on Neuronetics (STIM) with a Buy rating and $5 target as shares surge 28%. R

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's

BTIG analyst Sam Eiber initiates coverage on Neuronetics (NASDAQ:STIM) with a Buy rating and anno

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and

Business OutlookFor the second quarter of 2026, the Company expects total revenue growth in the mid-

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.16) per share which beat the analyst cons

This week's deal activity spans gaming, healthcare, energy, and private equity, with activist sa

On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by m

Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on des

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and low

Neuronetics (NASDAQ:STIM) sees FY2026 sales of $160.000 million-$166.000 million vs $164.167 million

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.10) per share which beat the analyst cons

Neuronetics shares jumped 41% in after-hours trading following strong preliminary fourth-quarter 202

Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a vertically integ

Neuronetics (NASDAQ:STIM) lowers FY2025 sales outlook from $149.000 million-$155.000 million to $147

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.13) per share which missed the analyst co

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and low

Neuronetics (NASDAQ:STIM) affirms FY2025 sales outlook from $149.000 million-$155.000 million to $14

Neuronetics (NASDAQ:STIM) sees Q3 sales of $37.000 million-$39.000 million vs $38.395 million analys

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.15) per share which missed the analyst co

Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutica

Neuronetics (NASDAQ:STIM) reported quarterly losses of $(0.21) per share which missed the analyst co

Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024a $0.6 million reduction in

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:STIM) with a Buy and rai

Citizens Capital Markets analyst Daniel Stauder maintains Neuronetics (NASDAQ:STIM) with a Market

Business OutlookFor the first quarter of 2025, the Company expects total worldwide revenue between $